JP2009531451A5 - - Google Patents

Download PDF

Info

Publication number
JP2009531451A5
JP2009531451A5 JP2009503167A JP2009503167A JP2009531451A5 JP 2009531451 A5 JP2009531451 A5 JP 2009531451A5 JP 2009503167 A JP2009503167 A JP 2009503167A JP 2009503167 A JP2009503167 A JP 2009503167A JP 2009531451 A5 JP2009531451 A5 JP 2009531451A5
Authority
JP
Japan
Prior art keywords
nsaid
pharmaceutical composition
parenteral administration
minimum approved
dosing amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531451A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/064683 external-priority patent/WO2007112274A2/en
Publication of JP2009531451A publication Critical patent/JP2009531451A/ja
Publication of JP2009531451A5 publication Critical patent/JP2009531451A5/ja
Pending legal-status Critical Current

Links

JP2009503167A 2006-03-28 2007-03-22 低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物 Pending JP2009531451A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78648706P 2006-03-28 2006-03-28
PCT/US2007/064683 WO2007112274A2 (en) 2006-03-28 2007-03-22 Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin

Publications (2)

Publication Number Publication Date
JP2009531451A JP2009531451A (ja) 2009-09-03
JP2009531451A5 true JP2009531451A5 (enExample) 2011-09-29

Family

ID=38541809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503167A Pending JP2009531451A (ja) 2006-03-28 2007-03-22 低投与量の非ステロイド系抗炎症薬及びβ−シクロデキストリンの配合物

Country Status (12)

Country Link
US (1) US20070232567A1 (enExample)
EP (1) EP2003970A4 (enExample)
JP (1) JP2009531451A (enExample)
KR (1) KR20090010953A (enExample)
CN (1) CN101410012A (enExample)
AU (1) AU2007230718B2 (enExample)
BR (1) BRPI0709410A2 (enExample)
CA (1) CA2647533A1 (enExample)
IL (1) IL194184A0 (enExample)
MX (1) MX2008012496A (enExample)
WO (1) WO2007112274A2 (enExample)
ZA (1) ZA200808114B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP2522343A1 (en) * 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS
WO2009089269A1 (en) * 2008-01-07 2009-07-16 Javelin Pharmaceuticals, Inc. Methods of treating pain while minimizing adverse effects on platelet function
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
GB201021267D0 (en) 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
MY166036A (en) * 2011-07-20 2018-05-21 Hospira Inc Methods of treating pain
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
CN103405782A (zh) * 2013-08-29 2013-11-27 江苏正大清江制药有限公司 一种含塞来昔布的包合物及其制备方法
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
JP6605047B2 (ja) 2015-05-28 2019-11-13 ドクター・レディーズ・ラボラトリーズ・リミテッド 疼痛治療のためのセレコキシブの経口用組成物
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
KR102583443B1 (ko) * 2017-05-10 2023-09-26 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학적 조성물
WO2019105957A1 (en) 2017-11-30 2019-06-06 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Stable liquid composition of ketoprofen, salts and enantiomers thereof
US20220280463A1 (en) 2019-09-09 2022-09-08 Ftf Pharma Private Limited Pharmaceutical formulations comprising diclofenac
CN114681470A (zh) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法
CN116421569B (zh) * 2023-06-15 2023-09-05 四川尚锐生物医药有限公司 一种注射用帕瑞昔布钠药物组合物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
NZ267417A (en) * 1993-06-08 1997-02-24 Ciba Geigy Ag An inclusion compound of diclofenac and gamma-cyclodextrin and compressed dosage forms thereof
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
US5866162A (en) * 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
ZA949182B (en) * 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
AU3609795A (en) * 1994-10-10 1996-05-02 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
ATE215821T1 (de) * 1995-01-20 2002-04-15 Wakamoto Pharma Co Ltd Entzündungshemmende augentropfen
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
HUP9600758A2 (en) * 1996-03-27 1998-03-02 Cyclolab Ciklodextrin Kutato F Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
IT1291362B1 (it) * 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7186260B2 (en) * 1999-04-29 2007-03-06 Hyson Morton I Medicated wrap
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
AU2001259816A1 (en) * 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP2004508334A (ja) * 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US20040137062A1 (en) * 2001-05-25 2004-07-15 Sham Chopra Chronotherapy tablet and methods related thereto
FR2830017B1 (fr) * 2001-09-27 2005-11-04 Centre Nat Rech Scient Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
WO2003033025A2 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
NZ540318A (en) * 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
JP2006509788A (ja) * 2002-11-27 2006-03-23 ファルマシア・コーポレーション バルデコキシブの濃縮液体組成物
EP1595936B1 (en) * 2003-01-27 2011-10-19 Vitamin C60 Bioresearch Corporation Composition for external use
KR20050111598A (ko) * 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 nsaid를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
EP1681065A4 (en) * 2003-10-31 2011-12-28 Wakamoto Pharma Co Ltd WATER-BASED COMPOSITION SUBJECTED TO REVERSIBLE THERMOREGULATION
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
DE602004025151D1 (de) 2004-03-10 2010-03-04 Shimoda Biotech Pty Ltd Stabile injizierbare Diclofenac- Zubereitungen
US8128954B2 (en) * 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
ITMI20041245A1 (it) * 2004-06-22 2004-09-22 Ibsa Inst Biochimique Sa Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DE602005027727D1 (de) * 2004-10-15 2011-06-09 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
EP1898922A4 (en) * 2005-07-04 2012-03-14 Ramu Krishnan MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine
EP1998788A4 (en) * 2006-03-01 2011-08-03 Ruey J Yu COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
EP2522343A1 (en) * 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
HUE052220T2 (hu) * 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 kötõfehérjék

Similar Documents

Publication Publication Date Title
NZ601529A (en) Tapentadol compositions
US10744143B2 (en) Therapeutic and method of use
CA2449098A1 (en) Pharmaceutical compositions for the coordinated delivery of nsaids
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
RU2008146815A (ru) Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол т нестероидный противовоспалительный препарат
JP2009531450A5 (enExample)
JP2011522035A5 (enExample)
JP2010031044A5 (enExample)
JP2014532728A5 (enExample)
JP2009543885A5 (enExample)
NZ582327A (en) Pharmaceutical combination of nsaid and prostaglandin compound
CA2459757A1 (en) Combination
FI3191120T3 (fi) Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
JP2018509470A5 (enExample)
JP2007512273A5 (enExample)
HRP20171651T1 (hr) (s)-pirlindol i njegove farmaceutski prihvatljive soli za uporabu u medicini
MX2009006575A (es) Terapia de combinacion de trastornos del tracto urinario inferior con ligandos a2d y farmacos anti-inflamatorios no esteroidales (nsaids).
JP2012506429A5 (enExample)
JP2016520556A5 (enExample)
RU2003100874A (ru) Болеутоляющие и противовоспалительные составы, содержащие ингибиторы циклооксигеназы-2
Hahn et al. Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer
CHOI et al. Update on NSAIDs related peptic ulcers
RU2025117613A (ru) Фармацевтическая композиция для профилактики или лечения пептической язвы, связанной с лекарственной терапией, содержащая застапразан или его фармацевтически приемлемую соль
RU2021114516A (ru) Многокомпонентная композиция для применения для устранения воспаления
RU2016106521A (ru) Способ обезболивания в стоматологии